These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18480302)

  • 1. RANKL is a mediator of bone resorption in idiopathic hypercalciuria.
    Gomes SA; dos Reis LM; Noronha IL; Jorgetti V; Heilberg IP
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1446-52. PubMed ID: 18480302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers.
    Menon VB; Moysés RM; Gomes SA; de Carvalho AB; Jorgetti V; Heilberg IP
    Clin J Am Soc Nephrol; 2014 Jul; 9(7):1263-70. PubMed ID: 24763863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does idiopathic hypercalciuria affect bone metabolism during childhood? A prospective case-control study.
    Pavlou M; Giapros V; Challa A; Chaliasos N; Siomou E
    Pediatr Nephrol; 2018 Dec; 33(12):2321-2328. PubMed ID: 30043116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
    Ricci P; Tauchmanova L; Risitano AM; Carella C; Mazziotti G; Lombardi G; Colao A; Rotoli B; Selleri C
    Transplantation; 2006 Dec; 82(11):1449-56. PubMed ID: 17164716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin mRNA in periodontal diseases.
    Bostanci N; Ilgenli T; Emingil G; Afacan B; Han B; Töz H; Berdeli A; Atilla G; McKay IJ; Hughes FJ; Belibasakis GN
    J Periodontal Res; 2007 Aug; 42(4):287-93. PubMed ID: 17559623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
    Armada L; Marotta Pdos S; Pires FR; Siqueira JF
    J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of serum osteoprotegerin and receptor-activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery.
    Balsa JA; Lafuente C; Gómez-Martín JM; Galindo J; Peromingo R; García-Moreno F; Rodriguez-Velasco G; Martínez-Botas J; Gómez-Coronado D; Escobar-Morreale HF; Botella-Carretero JI
    J Bone Miner Metab; 2016 Nov; 34(6):655-661. PubMed ID: 26438320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance is associated with HIV-induced bone loss in patients with higher CD4+ T-cell counts.
    Titanji K; Vunnava A; Foster A; Sheth AN; Lennox JL; Knezevic A; Shenvi N; Easley KA; Ofotokun I; Weitzmann MN
    AIDS; 2018 Apr; 32(7):885-894. PubMed ID: 29424771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
    Roux S; Mariette X
    Leuk Lymphoma; 2004 Jun; 45(6):1111-8. PubMed ID: 15359989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of receptor activator of nuclear factor kappa B ligand, osteoprotegerin and interleukin-33 on bone metabolism in patients with long-standing ulcerative colitis.
    Stanisławowski M; Wiśniewski P; Guzek M; Wierzbicki PM; Adrych K; Smoczyński M; Sworczak K; Celiński K; Kmieć Z
    J Crohns Colitis; 2014 Aug; 8(8):802-10. PubMed ID: 24439762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal and spatial expression of osteoprotegerin and receptor activator of nuclear factor -kappaB ligand during mandibular distraction in rats.
    Zhu WQ; Wang X; Wang XX; Wang ZY
    J Craniomaxillofac Surg; 2007 Mar; 35(2):103-11. PubMed ID: 17449257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of Toll-like receptor 4 decreases lipopolysaccharide-induced bone resorption in C3H/HeJ mice in vivo.
    Nakamura H; Fukusaki Y; Yoshimura A; Shiraishi C; Kishimoto M; Kaneko T; Hara Y
    Oral Microbiol Immunol; 2008 Jun; 23(3):190-5. PubMed ID: 18402604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
    Kostenuik PJ
    Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media.
    Kuczkowski J; Sakowicz-Burkiewicz M; Iżycka-Świeszewska E
    Am J Otolaryngol; 2010; 31(6):404-9. PubMed ID: 20015790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA.
    Arslan MS; Sahin M; Karakose M; Tutal E; Topaloglu O; Ucan B; Demirci T; Caliskan M; Ozdemir S; Ozbek M; Cakal E
    Endocr Pract; 2017 Mar; 23(3):266-370. PubMed ID: 27849387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling?
    Van Bezooijen RL; Papapoulos SE; Löwik CW
    Bone; 2001 Apr; 28(4):378-86. PubMed ID: 11336918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microRNA-143-3p regulates odontogenic differentiation of human dental pulp stem cells through regulation of the osteoprotegerin-RANK ligand pathway by targeting RANK.
    Yang C; Jia R; Zuo Q; Zheng Y; Wu Q; Luo B; Lin P; Yin L
    Exp Physiol; 2020 May; 105(5):876-885. PubMed ID: 32052500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
    Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
    Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.